Joseph Han, MD
Otolaryngology · Norfolk, VANPI 1760577985
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by GSK at 27.7% of the total. Among otolaryngology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,588 payments — averaging $1130.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$498K
- Optinose US, Inc.$317K
- Regeneron Healthcare Solutions, Inc.$282K
- Sanofi$265K
- Medtronic$109K
- AstraZeneca$86K
- plus $241K from 27 others
Across 364 payments — averaging $3092.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$252K
- Optinose US, Inc.$211K
- GSK$174K
- Sanofi US Services Inc.$136K
- Sanofi$136K
- Roche Products Limited$63K
- plus $154K from 7 others
What the payments were for
- Consulting fees$584,50933%
- Speaking & faculty fees$937,64552%
- Grants$7010%
- Travel & lodging$228,41113%
- Food & beverage$44,5642%
- Education$1720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 283 | $497,618 |
| Optinose US, Inc. | 348 | $316,647 |
| Regeneron Healthcare Solutions, Inc. | 222 | $281,782 |
| Sanofi | 170 | $264,775 |
| Medtronic(2 entities) | 148 | $108,628 |
| AstraZeneca | 130 | $85,858 |
| Aerin Medical Inc. | 55 | $65,681 |
| Regeneron | 20 | $26,102 |
| Astrazeneca UK Limited | 28 | $25,839 |
| Insmed, Inc. | 16 | $21,942 |
| Alk-abello, Inc | 31 | $21,255 |
| Intersect ENT, Inc. | 42 | $12,571 |
| Sanofi-aventis U.S. LLC | 5 | $12,164 |
| Sanofi US Services Inc. | 2 | $11,950 |
| Merck | 14 | $11,504 |
| Genentech, Inc. | 16 | $9,080 |
| F. Hoffmann-la Roche AG | 13 | $8,222 |
| Novartis | 7 | $4,872 |
| Paratek Pharmaceuticals, Inc. | 4 | $3,693 |
| Astrazeneca AB | 1 | $2,417 |
| Pfizer | 1 | $1,110 |
| Acclarent, Inc | 7 | $435 |
| Phadia US Inc. | 4 | $375 |
| Stryker | 4 | $339 |
| Integra Lifesciences Corporation | 3 | $299 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $256 |
| Genentech USA, Inc. | 5 | $222 |
| Grifols USA, LLC | 1 | $128 |
| Amgen | 1 | $80 |
| KARL Storz Endoscopy-america | 2 | $78 |
| Acera Surgical, Inc. | 1 | $40 |
| Johnson & Johnson | 1 | $24 |
| CSL Behring | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$534,270
- Xhance$312,565
- NUCALA$213,307
- RHINAER STYLUS$63,676
- TEZSPIRE$58,239
- VIVAER STYLUS$57,753
- FASENRA$31,883
- NUVENT$22,587
- XOLAIR$19,380
- PROPEL$14,272
- Odactra$14,106
- STRAIGHTSHOT$11,862
- FUSION$11,122
- STEALTHSTATION S8 PLATFORM$7,668
- AIRSUPRA$5,937
- StealthStation$4,914
- NUZYRA$3,685
- NOVAPAK$2,232
- Esbriet$2,200
- SINUVA$1,960
How this compares
$1,796,003 in reported general payments places this provider in the 95th percentile of 241 otolaryngology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 16 | $77,730 |
| XolairOmalizumab | 12 | $57,141 |
| XhanceFluticasone Propionate | 15 | $10,257 |
| RyaltrisOlopatadine Hcl/Mometasone | 12 | $2,938 |
| Ipratropium Bromide | 72 | $1,855 |
| Mupirocin | 97 | $914 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 24 | $374 |
| Montelukast Sodium | 24 | $360 |
| Doxycycline Hyclate | 16 | $251 |
| Fluticasone Propionate | 22 | $199 |
| Ciprofloxacin Hcl | 12 | $148 |
| Azelastine Hcl | 13 | $143 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $105 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $61 |
| Prednisone | 23 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $9,080 | $57,14112 claims |
| Optinose US, Inc.Xhance | $316,647 | $10,25715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 241 otolaryngology providers in Virginia.
Other otolaryngology in Norfolk
- Kent LamNorfolk$127K
- Craig DerkayNorfolk$21K
- David DarrowNorfolk$12K
- Laurence OhalloranAnnandale$2.9M
- Ryan NordRichmond$454K
- Paul LenkowskiRoanoke$282K
- Nipun ChhabraLeesburg$178K
- Spencer PayneCharlottesville$45K
- Jose MattosCharlottesville$24K
- Heath DreyfussMc Lean$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.